International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 3 , Pages 671-677 , 1 March 2008

Assessment of External Beam Radiation Technology for Dose Escalation and Normal Tissue Protection in the Treatment of Prostate Cancer

  • David J. D'Ambrosio, M.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Alan Pollack, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Eleanor E.R. Harris, M.D.

      Affiliations

    • Division of Radiation Oncology, H. Lee Moffit Cancer Center, Tampa, FL
    • ,
  • Robert A. Price Jr., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • Lynn J. Verhey, Ph.D.

      Affiliations

    • Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA
    • ,
  • Mack Roach III, M.D.

      Affiliations

    • Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, CA
    • ,
  • D. Jeffrey Demanes, M.D.

      Affiliations

    • California Endocurietherapy Cancer Center (CET), Oakland, CA
    • ,
  • Michael L. Steinberg, M.D.

      Affiliations

    • Santa Monica Cancer Treatment Center, Santa Monica, CA
    • ,
  • Louis Potters, M.D.

      Affiliations

    • Department of Radiation Oncology, South Nassau Communities Hospital, Oceanside, NY
    • ,
  • Paul E. Wallner, D.O.

      Affiliations

    • 21st Century Oncology, Moorestown, NJ
    • ,
  • Andre Konski, M.D., M.B.A., M.A.

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA
    • Corresponding Author InformationReprint requests to: Andre Konski, M.D., M.B.A., M.A., Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. Tel: (215) 728-2940; Fax: (215) 214-1629

Received 11 April 2007 ,Revised 14 September 2007 ,Accepted 14 September 2007.

References 

  1. Surveillance, Epidemiology, and End Results SEER Program. SEER∗Stat Database: Incidence and mortality. Available at: http://seer.cancer.gov/. Accessed May 4, 2007.
  2. Fletcher GH, Shukovsky LJ. The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl. 1975;56:383–400
  3. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: An update of the fox chase experience. J Urol. 2004;171:1132–1136
  4. Jacob R, Hanlon AL, Horwitz EM, et al. Role of prostate dose escalation in patients with >15% risk of pelvic lymph-node involvement. Int J Radiat Oncol Biol Phys. 2003;57:S150
  5. Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1074–1081
  6. Hanlon AL, Horwitz EM, Buyyounouski MK, et al. 2244: Adjusted radiotherapy dose response curves following treatment for prostate cancer: Biochemical failure and distant metastasis. Int J Radiat Oncol Biol Phys. 2006;66:S346–S347
  7. Jacob R, Hanlon AL, Horwitz EM, et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004;100:538–543
  8. Nguyen KH, Horwitz EM, Hanlon AL, et al. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;57:377–383
  9. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Red J. 2000;48:507–512
  10. Cheung R, Tucker SL, Dong L, et al. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:1234–1240
  11. Cheung R, Tucker SL, Lee AK, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:993–1002
  12. Vora SA, Wong WW, Schild SE, et al. 2288: Analysis of biochemical control and prognostic factors in patients treated with either low dose 3-dimensional conformal radiation therapy or high dose IMRT for localized prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S370
  13. Symon Z, Griffith KA, McLaughlin PW, et al. Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys. 2003;57:384–390
  14. Karlsdottir A, Paul Muren L, Wentzel-Larsen T, et al. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncol. 2006;45:454–462
  15. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468
  16. Mackley HB, Reddy CA, Reuther AM, et al. 2218: Relapse-free survival with escalating external beam radiation doses in the treatment of localized prostate cancer: 74 Gy at 2 Gy, 78 Gy at 2 Gy, and hypofractionated 70 Gy at 2.5 Gy per fraction. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S331
  17. Zelefsky MJ, Hunt MA, Fuks Z, et al. 16: Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S9
  18. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  19. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  20. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  21. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  22. Pisansky TM, Thames HD, Levy LB, et al. Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer. [Abstract] Int J Radiat Oncol Biol Phys. 2004;60(Suppl.):S167
  23. Bey P, Carrie C, Ginestet C, et al. French study of dose escalation from 66 to 80 GY with 3D-CRT in prostate cancer: results at 5 years. Int J Radiat Oncol Biol Phys. 2003;57:S272
  24. Bey P, Carrie C, Beckendorf V, et al. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer—Preliminary results. Red J. 2000;48:513–517
  25. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  26. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys. 1995;32:3–12
  27. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  28. Kuban D, Tucker S, Dong L, et al. 15: Long-term results of a randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:S8–S9
  29. Pollack A, Zagars GK, Antolak JA, et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 2002;54:677–685
  30. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  31. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  32. Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol. 1999;9:79–98
  33. Vargas C, Martinez A, Kestin LL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1297–1308
  34. Madsen B, Pham H, Hsi RA, et al. Comparison of rectal dose volume histograms for definitive prostate radiotherapy among stereotactic radiotherapy, IMRT, and 3D-CRT techniques. [Abstract] Int J Radiat Oncol Biol Phys. 2004;60(Suppl.):S633
  35. Tucker SL, Dong L, Cheung R, et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1589–1601
  36. Shahar KH, McGary JE, Mai W, et al. Retrospective analysis of late rectal bleeding in prostate cancer patients treated with intensity modulated radiotherapy (IMRT). [Abstract] Int J Radiat Oncol Biol Phys. 2004;60(Suppl.):S459
  37. Fiorino C, Sanguineti G, Cozzarini C, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57:953–962
  38. Shippy AM, Hunt MA, Yamada Y, et al. 58: Long-term toxicity outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:S34
  39. Cahlon O, Zelefsky M, Shippy A, et al. 59: Intensity modulated radiation therapy to a dose of 86.4 gy for localized prostate cancer: toxicity data and preliminary biochemical outcomes. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S33–S33
  40. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  41. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241–249
  42. Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: A review. Int J Radiat Oncol Biol Phys. 2002;52:681–693
  43. Su AW, Gratzle J, Correa D, et al. 2294: Comparison of chronic GI and GU toxicity of patients with prostate cancer undergoing IMRT vs conventional radiotherapy using localized fields. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S374
  44. Kirichenko AV, Ruth K, Horwitz EM, et al. 2209: Intensity modulated radiation therapy for prostate cancer: preliminary results on treatment morbidity compared to 3-D conformal radiation therapy. [Abstract] Int J Radiat Oncol Biol Phys. 2006;66(Suppl.):S326
  45. Roach M, Winter K, Michalski JM, et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int J Radiat Oncol Biol Phys. 2004;60:1351–1356
  46. Sethi A, Mohideen N, Leybovich L, et al. Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2003;55:970–978
  47. Buyyounouski MK, Horwitz EM, Uzzo RG, et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2004;59:1383–1391
  48. Kao J, Turian J, Meyers A, et al. Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer. Br J Radiol. 2004;77:129–136
  49. Buyyounouski MK, Horwitz EM, Price RA, et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2004;58:743–749
  50. Chao ST, Reddy CA, Thakkar VV, et al. Impact of high-dose radiation on erectile function in patients treated with intensity-modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:S270–S271
  51. D'Ambrosio D, Zelefsky M, Chan H, et al. Prognostic factors for maintained efficacy of Sildenafil citrate in the management of erectile dysfunction after radiotherapy for prostate cancer. [Abstract] IInt J Radiat Oncol Biol Phys. 2003;57(Suppl.):S274
  52. Mangar SA, Sydes MR, Tucker HL, et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: Using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother Oncol. 2006;80:355–362
  53. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036–1046
  54. Ritter MA, Forman JD, Petereit DG, et al. 19: Dose-per-fraction escalation for localized prostate cancer—A multi-institutional phase I/II Trial. Int J Radiat Oncol Biol Phys. 2006;66:S11–S11
  55. Little DJ, Kuban DA, Levy LB, et al. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003;62:707–713
  56. Beckendorf V, Guerif S, Le Prise E, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1056–1065
  57. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998;159:1988–1992
  58. Wilson LS, Elkin EP, Sadetsky N, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518–527
  59. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000;92:1731–1739
  60. Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis. 2002;5:164–166
  61. Stewart ST, Lenert L, Bhatnagar V, et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347–355
  62. Konski A, Watkins-Bruner D, Feigenberg S, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:408–415
  63. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer. 2001;92:2796–2810

 Supported by departmental Varian research grant (A.P.); Departmental Siemens research grant (L.J.V.); ASTRO IMRT/3D-CRT Practicum faculty (R.A.P.); honoraria: Siemens (M.R.), ASTRO (M.R., P.E.W.), Nomos (M.L.S.), Glaxo Smith Kline (P.E.W.); Oncura and Theragenics meeting grant (L.P.).

PII: S0360-3016(07)04261-7

doi: 10.1016/j.ijrobp.2007.09.034

International Journal of Radiation Oncology * Biology * Physics
Volume 70, Issue 3 , Pages 671-677 , 1 March 2008

Article Tools